Trial · NCT04616729
DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation
NCT04616729, Phase 1, Phase 2, Unknown, Universitair Ziekenhuis Brussel
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation. Trials, record NCT04616729. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04616729
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation
- NCT number
- NCT04616729
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Conditions
- Breast Cancer Female
- Interventions
- Triptorelin 3.75 MG Injection, Transvaginal oocyte retrieval, Triptorelin Injection
- First posted
- 2020-11-05
- Last updated
- 2023-05-18
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in ovarian volume | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A transvaginal ultrasound will be performed to measure the ovarian volume according to the formula 'length x width x height x 0.523' mm³. In the assumption of safety ovarian volume should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in hematocrit | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate hematocrit (%). In the assumption of safety hematocrit levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in hemoglobine | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate hemoglobine (g/dL). In the assumption of safety hemoglobine levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in White Blood cell Count | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate White Blood cell Count (X10³/mm³). In the assumption of safety White Blood cell Count should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Platelet Count | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Platelet Count (X10³/mm³). In the assumption of safety Platelet Count should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in estimated glomerular filtration rate (eGFR) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate eGFR (mL/min/1.73m²). In the assumption of safety eGFR levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Creatinine | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Creatinine (mg/dL). In the assumption of safety creatinine levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Albumin | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Albumin (g/L). In the assumption of safety Albumin levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in liver function (AST, ALT, Gamma-GT, bilirubine, LDH) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate liver function (AST U/L, ALT U/L, Gamma-GT U/L, bilirubine mg/dL, LDH U/L). In the assumption of safety liver function levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
| Primary | Safety profile with regard to the risk of OHSS: assessment of change in Oestradiol (E2) | During one week after the transvaginal oocyte retrieval (on day 3, 5 and 7) | A blood sample will be taken to evaluate Oestradiol (ng/L). In the assumption of safety Oestradiol levels should be similar to that in the control group and there should be no events of ovarian hyperstimulation syndrome. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04616729
GET https://conductscience.org/api/trials/v1/NCT04616729/registered